Oxygenta Pharmaceutical Ltd (OXYGENTAPH) — shareholding pattern, promoter holding, financials and share price
About Oxygenta Pharmaceutical Ltd (OXYGENTAPH)
Oxygenta Pharmaceutical Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as OXYGENTAPH and on the BSE under scrip code 524636. Its ISIN is INE102E01018.
Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.
Oxygenta Pharmaceutical Limited, formerly S S Organics Ltd, specializes in manufacturing anti-ulcerative and antibacterial drugs, alongside other pharmaceuticals.
The company engages in both contract manufacturing and independent production, supporting its revenue through strategic partnerships.
Listed peers in Pharmaceuticals: Achyut Healthcare Ltd, Accretion Nutraveda Ltd, Sanjivani Paranteral Ltd, Accretion Pharmaceuticals Ltd, Parnax Lab Ltd, Bio Medica Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹48.25 a share on 10 Jul 2026, Oxygenta Pharmaceutical Ltd (OXYGENTAPH) was valued at a price-to-earnings ratio of -10.18x against an industry P/E of 36.41x. Solomo computes return on equity of 41.16% and return on capital employed of -46.82% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -10.18x
- Industry P/E
- 36.41x
- EPS (TTM)
- ₹-4.75
- Book value / share
- ₹-6.77
- ROE
- 41.16%
- ROCE
- -46.82%
- ROA
- -21.07%
- Debt / equity
- -2.57x
- Dividend yield
- 0%
- EBITDA margin
- -13.36%
- 52-week range
- ₹46.6 – ₹48.74
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Oxygenta Pharmaceutical Ltd (OXYGENTAPH) reported revenue of ₹113 crore, net profit of ₹-18 crore and earnings per share of ₹-4.75. That compares with revenue of ₹109 crore and net profit of ₹-10 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹49.61 crore and net profit ₹-1.7 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 61 | 31 | 40 | 109 | 113 |
| Net profit (₹ cr) | -1 | -12 | -3 | -10 | -18 |
| EPS (₹) | -0.43 | -8.15 | -1.04 | -2.62 | -4.75 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 27.33% | 51.45% | 21.78% | 175.73% |
| Profit growth | - | - | - | -178.16% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 56.54% of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.03%. Market capitalisation was ₹178 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: SRAVANI REDDY GANTLA 6.78%, SUBBA REDDY BHIMAVARAPU 4.14%, SUNIL V. CHAWDA 2.97%, KUMUDA KATASANI 2.27%, MANOJ S. CHAWDA 1.54%, AAKANKSHA M CHAWDA 1.54%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 56.54% | - | - | 0.03% | 43.46% |
| Mar 2026 | 56.54% | - | - | 0.03% | 43.46% |
| Dec 2025 | 55.93% | - | - | 0.03% | 44.07% |
| Sep 2025 | 57.95% | - | - | 0.03% | 42.05% |
| Jun 2025 | 57.95% | - | - | 0.03% | 42.05% |
| Mar 2025 | 51.12% | - | - | 0.03% | 48.88% |
| Dec 2024 | 51.12% | - | - | 0.03% | 48.88% |
| Sep 2024 | 53.28% | - | - | 0.03% | 46.72% |